Bimekizumab治疗中重度斑块状银屑病的IIa期随机双盲多中心研究:疗效、安全性、药代动力学、药效学及转录组学
结果显示第8周47%患者达PASI 100,第12周升至57%,第16周给药组第20周PASI 100回升至峰值但第28周降至41%;皮损转录组快速正常化,支持III期评估每4周和每8周维持给药。
要点
- Bimekizumab 320 mg在第0/4周给药后,第8周47%、第12周57%患者达PASI 100。
- 第16周再次给药后PASI 100第20周回升至峰值,但第28周降至41%。
- 皮损转录组第8周快速正常化,包括IL17和IL23基因表达正常化。
核心结论
- 抑制IL-17F联合IL-17A可产生快速、深度的临床应答,并显著正常化角质形成细胞生物学和银屑病转录组。
- 数据支持在III期临床试验中评估Bimekizumab每8周和每4周维持给药方案。
研究设计与样本
- 患者第0/4周接受Bimekizumab 320 mg,第16周随机给予Bimekizumab 320 mg(n=17)或安慰剂(n=32),评估至第28周。
主要发现
- 第8周47%患者达PASI 100,第12周升至57%,随后下降。
- 第16周接受Bimekizumab者第20周PASI 100回升至可比峰值,第28周降至41%。
- 第8周皮损转录组快速正常化至与非皮损皮肤一致,达到分子缓解。
- CXCL1、IL-8(CXCL8)、CCL20、IL-36γ和IL-17C等角质形成细胞相关基因产物显著正常化至非皮损水平。
临床怎么用
- Bimekizumab可快速深度清除皮损,但维持治疗需关注给药间隔,每8周和每4周方案值得进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, which is currently under investigation for treatment of moderate-to-severe plaque psoriasis. Maintenance dosing every 4 weeks is well established with IL-17 inhibitors for psoriasis. OBJECTIVES: To investigate the possible dosing interval during bimekizumab maintenance therapy to maintain clear skin, to inform phase III studies. METHODS: Forty-nine patients with moderate-to-severe plaque psoriasis received bimekizumab 320 mg at weeks 0/4, followed at week 16 by bimekizumab 320 mg (n = 17) or placebo (n = 32). Efficacy, safety, pharmacokinetics, immunogenicity and biopsy transcriptomic analyses were assessed to week 28. RESULTS: At week 8, 47% of patients achieved a 100% improvement from baseline in Psoriasis Area and Severity Index (PASI 100), increasing to 57% at week 12 (8 weeks after the second dose) before decreasing. In those who received bimekizumab at week 16, PASI 100 rate increased to comparable peak levels at week 20, but reduced by week 28 to 41% (12 weeks after the third dose). The week 8 transcriptional signature observed in lesional psoriatic skin rapidly normalized to levels consistent with nonlesional skin, resulting in molecular remission. Keratinocyte-related gene products such as CXCL1 (C-X-C motif chemokine ligand 1), IL-8 (encoded by the CXCL8 gene), CCL20 (C-C motif chemokine 20), IL-36γ and IL-17C were profoundly normalized to levels associated with nonlesional skin. CONCLUSIONS: Here, inhibition of IL-17F in addition to IL-17A resulted in rapid, deep clinical responses. Additionally, profound normalization of keratinocyte biology and the psoriatic transcriptome was observed, including normalization of both IL17 and IL23 gene expression by week 8. These data provide evidence to support evaluation of bimekizumab maintenance dosing both every 8 and every 4 weeks in phase III clinical trials.
引用
- Oliver R, Krueger JG, Glatt S, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2021. PMID: 34687214. doi:10.1111/bjd.20827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。